Skip to content

Press Release

DH endorses recall of Candinox Vaginal Tablet 100mg

15 June 2016

The Department of Health (DH) today (June 15) endorsed a licensed drug wholesaler, Deltapharm Ltd, to recall all batches of Candinox Vaginal Tablet 100mg (registration number: HK-41076) from shelves due to a quality issue.

During the DH's market surveillance, samples of the above pharmaceutical product were collected for analysis. Testing results from the Government Laboratory showed that all samples failed the disintegration test, which might affect the efficacy of the product. Deltapharm hence recalled the product from the market.

"We have instructed Deltapharm to report the root cause upon investigation by the manufacturer in Thailand. Our investigation is continuing," a spokesman for the DH said.

According to Deltapharm, the product has been supplied to local private doctors and pharmacies, and exported to Macau.

The above pharmaceutical product contains a Part 1 poison, clotrimazole, and is used for the treatment of vulvovaginal candidiasis. It can only be supplied at a pharmacy under the supervision of a registered pharmacist.

Deltapharm has set up a hotline (3113 6103) to answer related enquiries. The DH will closely monitor the recall.

So far, the DH has not received any adverse reaction reports in connection with the above product.

People who have used the above product should consult their healthcare professionals when in doubt or feeling unwell after use.

Candinox Vaginal Tablet 100mg, which is under recall.

15 June 2016